メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
岡山大学 ホーム
English
日本語
岡山大学でコンテンツを検索
ホーム
プロファイル
研究部門
研究成果
設備
活動
プレス/メディア
受賞
Scopus著者プロファイル
濱野 裕章
講師
,
岡山大学病院
h-index
852
被引用数
16
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2011
2026
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(83)
類似のプロファイル
(6)
フィンガープリント
Hirofumi Hamanoが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Pharmacovigilance
42%
Disproportionality Analysis
35%
Immune Checkpoint Inhibitor
32%
Nephrotoxicity
29%
Vancomycin
29%
Mouse
26%
Retrospective Study
25%
Cisplatin
24%
Myocarditis
24%
Adverse Drug Reaction
22%
Acute Kidney Failure
21%
Statin (Protein)
19%
Interstitial Lung Disease
18%
Proton Pump Inhibitor
18%
Kidney Injury
17%
Malignant Neoplasm
17%
Cardiotoxicity
16%
Trastuzumab
13%
Congestive Heart Failure
12%
Hepcidin
11%
Cardiovascular Toxicity
11%
Irinotecan
11%
Oxaliplatin-Induced Peripheral Neuropathy
11%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
10%
Drug Repositioning
10%
Daptomycin
9%
Osimertinib
9%
Rhabdomyolysis
9%
Breast Cancer
9%
Epidermal Growth Factor Receptor Kinase Inhibitor
9%
Drug Discovery
8%
Chemotherapy
8%
Concomitant Drug
8%
Chronic Kidney Failure
7%
Pertuzumab
7%
Vasculotropin
7%
Lung Cancer
7%
Aromatic Hydrocarbon Receptor
7%
Therapeutic Effect
7%
Neutropenia
7%
Prevalence
6%
Thiazide Diuretic Agent
6%
Pembrolizumab
6%
Ipilimumab
6%
Nivolumab
6%
Clinical Study
6%
Piperacillin Plus Tazobactam
6%
Epidermal Growth Factor Receptor
6%
Rash
6%
Keyphrases
Real-time Database
17%
Statins
17%
Immune Checkpoint Inhibitors
15%
VigiBase
13%
World Health Organization
13%
Japan
12%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
12%
Concomitant Use
12%
Mortality Databases
11%
Oxaliplatin-induced Neuropathy
11%
Confidence Interval
10%
Myocarditis
10%
Osimertinib
8%
Standardized Mortality Ratio
8%
FDA Adverse Event Reporting System (FAERS)
7%
Disproportionality Analysis
7%
Drug pipeline
7%
Pharmacovigilance Database
6%
Rash
6%
Japanese Claims Database
6%
University Hospital
6%
Thiazide Diuretics
5%
Cisplatin-induced Kidney Injury
5%
Nephrotoxin
5%
Vancomycin
5%
Life-science Databases
5%
Big Data Analysis
5%
Interstitial Lung Disease
5%
Medical Sciences
5%
Synthase-dependent Pathway
5%
Patient Analysis
5%
Retrospective Analysis
5%
Pretreatment Effect
5%
Lung Cancer Patients
5%
Ferroptosis
5%
Factor Xa Inhibitors
5%
Spontaneous Reporting Database
5%
Renoprotective Effect
5%
Pemetrexed
5%
Database Analysis
5%
Nicardipine Hydrochloride
5%
Real-world Pharmacovigilance
5%
Low-dose Corticosteroids
5%
Kidney Toxicity
5%
Triple Whammy
5%
Iron Restriction
5%
Pre-exposure Prophylaxis (PrEP)
5%
Protein Overload
5%
Dietary Iron
5%
Drug Repositioning
5%
Medicine and Dentistry
Adverse Event
17%
Mortality Rate
13%
Nephrotoxicity
11%
Vancomycin
11%
Pharmacovigilance
11%
In Vitro
7%
Oxidative Stress
7%
Macrophage
7%
Immune Checkpoint Inhibitor
6%
Clinical Trial
6%
Immune-Related Adverse Events
6%
Drug Therapy
5%
Interstitial Lung Disease
5%
Cancer Cell
5%
Lung Cancer
5%
Clinical Study
5%
Ferritin
5%
Epidermal Growth Factor Receptor
5%
Blood Clotting Factor 10a Inhibitor
5%
Erythropoietin
5%
Head and Neck Cancer
5%
Cancer Mortality
5%
Diabetes
5%
Prothrombin
5%
Cabozantinib
5%
Vonoprazan
5%
Vasopressin Receptor Antagonist
5%
Hypoxia Inducible Factor
5%
Lipid Diet
5%
Nivolumab
5%
Ipilimumab
5%
Proton-Pump Inhibitor
5%
Vasculotropin
5%
Ureter Obstruction
5%
Cost-Effectiveness Analysis
5%
Biosimilar
5%
Trastuzumab
5%
Antiinfective Agent
5%
Sunitinib
5%
In Silico
5%
Calcitriol
5%
Mycobacterial Disease
5%
Biliary Tract Cancer
5%
Observational Study
5%
Mogamulizumab
5%
Pulmonary Embolism
5%
